Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 15, 2017 16:05 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion to Present at the 2017 JMP Securities Life Sciences Conference

NEW HAVEN, Conn., June 15, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion,...
June 05, 2017 16:51 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion to Present at the Jefferies 2017 Global Healthcare Conference

NEW HAVEN, Conn., June 05, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that members of the Achillion management team will present a corporate overview at...
May 04, 2017 06:05 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Reports First Quarter 2017 Financial Results and Provides Update on Clinical Programs

NEW HAVEN, Conn., May 04, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three months ended March 31, 2017. For the first quarter of...
May 02, 2017 06:05 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion to Present at the Deutsche Bank 42nd Annual Health Care Conference

NEW HAVEN, Conn., May 02, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion,...
April 22, 2017 03:00 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Announces Additional Phase 2 Results Including 100% SVR24 for Genotype 1 HCV After 6-Weeks of Once Daily JNJ-4178

AMSTERDAM, the Netherlands, April 22, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today the presentation of updated results from the ongoing phase 2 ‘604 Study’...
April 06, 2017 06:05 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Announces Initiation of Patient Dosing in Phase 2 Study of ACH-4471 for Paroxysmal Nocturnal Hemoglobinuria

NEW HAVEN, Conn., April 06, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced initiation of patient dosing in a Phase 2 open-label study of ACH-4471,...
March 21, 2017 16:05 ET | Source: Achillion Pharmaceuticals, Inc.

USPTO Grants Composition of Matter Patent to Achillion for Small Molecule Complement Alternative Pathway Factor D Inhibitors

NEW HAVEN, Conn., March 21, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that the U.S. Patent and Trademark Office (USPTO) has issued the first U.S. Patent...
February 28, 2017 06:05 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Pharmaceuticals to Support a Natural History Study of C3 Glomerulopathy, a Rare Renal Disorder, Conducted by Experts at Imperial College London

Three-year study commenced to include up to 400 patientsNatural history studies track course of a disease over time; can inform and support development and approval of new treatments for patientsC3...
February 23, 2017 16:05 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Reports 2016 Fourth Quarter and Year-End Financial Results

Complement factor D inhibitor program on track for initiation of ACH-4471 phase II trial for treatment-naïve PNH patients during the first half of 2017Expanding complement platform includes internally...
February 13, 2017 06:05 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion to Present at the Leerink Partners 6th Annual Global Healthcare Conference

NEW HAVEN, Conn., Feb. 13, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion,...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right